Mark Cuban's Cost Plus Drug Com­pa­ny adds new SGLT2 in­hibitor Bren­zavvy for type 2 di­a­betes

Mark Cuban’s Cost Plus Drug Com­pa­ny is bring­ing an­oth­er brand-name type 2 di­a­betes treat­ment un­der its wing.

Ther­a­cos­Bio’s re­cent­ly ap­proved SGLT2 in­hibitor Bren­zavvy is now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER